Index

Note: Page numbers of chapter titles are in **boldface** type.

ADENOMA, toxic solitary, 232-234
Anti-thyroid drugs—
  fetal effects of, 122-124
  in treatment of Graves' disease, 137-139
Autoimmune disease—
  experimental production of, 5-6
  role of macrophage in, 15-16
Autoimmunity—
  familial predisposition to, 48-50
    chromosomal abnormalities and, 49
    immunodeficiency diseases and, 49-50
    with related conditions, 49
    with related disorders, 48
  gastric, 49-50
    relationship of HLA-B8(-Dw3) to, 57-58
  thyroid, relationship of HLA-B8(-Dw3) to, 57-58
Autonomous function, in the thyroid, hyperthyroidism from, **177-197**

CARCINOMA, thyroid, 210-211
Catecholamine, depletion of in treatment of thyrotoxicosis, 224-225
Childhood—
  hyperthyroidism in, **127-143**
  treatment of Graves' disease in, 228-229
Choriocarcinoma—
  hyperthyroidism from, 211-212
  management of, 172-173
Chromosomal abnormalities, thyroid autoimmunity and, 49

DRUG THERAPY, in treatment of thyrotoxicosis, 221-225

EXOPHTHALMOS-PRODUCING SUBSTANCE, thyrotrophin and, 67-68
Extra-ocular muscles—
  in endocrine ophthalmopathy, 74-75
  surgery to in treatment of endocrine ophthalmopathy, 87
Eyelids, surgery to in treatment of endocrine ophthalmopathy, 87-89

FETUS, effect of anti-thyroid therapy on, 122-124

GOITRE, toxic multinodular, 233-234
Graves' disease—
  disorders associated with, 136
  genetics of, 17-19, **47-65**
    aetiological heterogeneity, 59
    familial predisposition to, 47-50
    HLA association with, 50-56
    interrelationships of factors, 56-58
    monogenic inheritance, 58-59
    multifactorial inheritance, 59
  humoral immunity in, **31-45**
  hyperthyroidism in, stress in the induction of, 19-20
  immune stigmata in, 4-17
  in childhood, 127-131
  neonatal, 131-134
  ophthalmopathy of, *see* Ophthalmopathy
  pathogenesis of, **3-29**
  remissions in, 20-21
  treatment of, 137-142, 227-232
    adults, 229-232
    anti-thyroid drugs, 137-139
    childhood, 228-229
    neonatal, 227
    radioiodine, 139-140
    surgery, 140-142
Guanethidine eye drops, in treatment of endocrine ophthalmopathy, 83

HASHIMOTO'S DISEASE, 209-210
  genetics of, 17-19
  immune stigmata in, 4-17
Histocompatibility antigens—
  as a genetic marker in Graves' disease, 50-56
  disease associations, 51-56
    biological significance of, 53-55
    in Graves' disease, 53
    with HLA-B8 (Dw3), 55-56
  linkage dysequilibrium and, 51
  the major complex, 50-51
HLA, *see* Histocompatibility antigens
Human thyroid gland, in assay of LATS, 34, 38-42
Hyperthyroidism, *see also* Thyrotoxicosis—
  associated with thyroiditis, 134-135
  autonomous functioning thyroid nodule, **177-197**

causes of, 97-99
diagnosis of, **97-113**
due to abnormal thyroid stimulators, 211-212
choriocarcinoma, 211-212
molar pregnancy, 211-212
non-trophoblastic tumours, 212
due to excess of exogenous thyroid hormone, 212
due to trophoblastic hormone, **167-175**
clinical manifestations, 168-170
identification of the thyroid stimulator, 171-172
management of, 172-173
familial predisposition to, 47-48
family studies, 47
twin studies, 48
in childhood, **127-143**
in vivo isotopic tests, 106-107
thyroid radioiodine uptake, 106-107
thyroid scans, 107
manifestations of, 99-101
clinical findings, 99-100
laboratory abnormalities, 100-101
maternal-fetal considerations, **115-125**
molecular mechanisms in, **145-165**
amplified response, 158-160
post-receptor, 155-158
practical aspects, 145-147
the nuclear receptor, 147-155
stress in the induction of, 19-20
suspected, approach to patients with, 110-111
thyroid hormone levels in, 104-106
thyroid hormone production in, 101-102
unusual types of, **199-220**

IMMUNITY—
cell-mediated, 70
in thyroid disease, 11-15
humoral—
in Graves' disease, **31-45**
in thyroid disease, 6-11
Immunodeficiency disease, thyroid and gastric autoimmunity in, 49-50
Iodides, in treatment of thyrotoxicosis, 223
Iodine—
in the induction of thyrotoxicosis, 205-208
in treatment of Graves' disease, 139-140
in treatment of thyrotoxicosis, 225-226

LARGE AUTONOMOUS MULTINODULAR THYROID (LAMT), 187-196
Linkage dysequilibrium, 51
Lithium, in treatment of thyrotoxicosis, 223-224
Long acting thyroid stimulator (LATS), 32-44
assays for using human thyroid glands, 34
direct assay of thyroid-stimulating antibody, 34-38
protector assay, 38-39
relationship to thyroid stimulating antibody, 42-44
Lymphocyte, sensitized, role of in Graves' disease, 16-17

MACROPHAGE, role of in autoimmune thyroid disease, 15-16
McCune-Albright syndrome, 135-136
Molecular mechanisms in hyperthyroidism, **145-165**
amplified response, 158-160
pathophysiological implications, 158-160
post-receptor, 155-158
practical aspects, 145-147
the nuclear receptor, 147-155

OPHTHALMOPATHY, endocrine—
aetiological concepts, 67-70
diagnosis of, 76-81
disordered thyroid function or regulation, 80-81
exclusion of alternative ocular diagnosis, 78-79
specificity of eye findings, 77-78
management of, **67-96**
pathogenesis of in Graves' disease, 21-22
pathology of, 73-76
extra-ocular muscles, 74-75
optic nerves, 75-76
presentation of, **67-96**
clinical, 70-73
treatment of, 81-89
extra-ocular muscle surgery, 87
eyelid surgery, 87-89
guanethidine eyedrops, 83
orbital decompression, 85-87
orbital radiotherapy, 84
steroid therapy, 84-85
thyroid ablation, 83-84
Optic nerves, in endocrine ophthalmopathy, 75-76
Orbital decompression, in treatment of endocrine ophthalmopathy, 85-87

PITUITARY-THYROID INTEGRITY, tests of, 108-109
thyroid suppression test, 109
TRH stimulation test, 108-109
Placenta, transfer across of thyroid hormone, 118-119
Polyostotic fibrous dysplasia, 135-136
Pregnancy—

molar, hyperthyroidism from, 211-212
treatment of thyrotoxicosis in, 119-124, 234-235

RADIOTHERAPY, orbital, in treatment of endocrine ophthalmopathy, 84
Receptors, for thyroid hormones, 147-155

STEROID THERAPY, in treatment of endocrine ophthalmopathy, 84-85
Stress, in induction of hyperthyroidism in Graves' disease, 19-20
Struma ovarii, 212-213
Surgery, in the treatment of thyrotoxicosis, 226-227

THIONAMIDES, in treatment of thyrotoxicosis, 221-223
Thyroglobulin antibodies, 69-70
Thyroid ablation—
in treatment of endocrine ophthalmopathy, 83-84
in treatment of thyrotoxicosis, 225-227
Thyroid carcinoma, 210-211
Thyroid disease, immunity in, 5-17
Thyroid hormones—
placental transfer of, 118-119
production of, 101-102
serum determinations of, 102-106
the nuclear receptor for, 147-155
Thyroiditis, 208-210
Hashimoto's, 209-210
in association with hyperthyroidism, 134-135
painless, treatment of, 236
subacute, 208-209
treatment of, 235-236
Thyroid, large autonomous multinodular, 187-196
Thyroid nodule, autonomous functioning, 177-187
Thyroid physiology—
fetal, 115-119
maternal, 115-119
Thyroid radioiodine uptake, use of in diagnosis of hyperthyroidism, 106-107
Thyroid scans, use of in diagnosis of hyperthyroidism, 107
Thyroid-stimulating antibody (TSAb), *see also* LATS, 32-44
assay of, via binding to human thyroid, 38-42
by interference with thyrotrophin, 39-42
LATS-protector assay, 38-39
direct assay of, 34-38
recognition of, implications of, 44
relationship of LATS to, 42-44
Thyroid-stimulating immunoglobulins, 68-69
serum concentrations of in hyperthyroidism, 107
Thyroid storm, treatment of, 235
Thyroid suppression test, 109
Thyrotoxicosis, *see also* Hyperthyroidism—
associated with thyroid hormone ingestion, 213
factitious, 212
treatment of, 236
iodine-induced, 205-208
treatment of, 236
T_3, 136
therapeutic considerations, **221-240**
approach to treatment, 227-236
drug therapy, 221-225
thyroid ablation, 225-227
treatment of during pregnancy, 119-124
Thyrotrophin (TSH)—
assay for, action of TSAb in, 39-42
exophthalmos-producing substance and, 67-68
hyperthyroidism due to excess secretion of, 199-205
-releasing hormone (TRH) stimulation test, 108-109
serum concentrations of in hyperthyroidism, 107
Trophoblastic hormone, hyperthyroidism due to, **167-175**
clinical manifestations, 168-170
identification of the thyroid stimulator, 171-172
management of, 172-173

Index

Note: Page numbers of chapter titles are in **boldface** type.

ACANTHOCYTOSIS, 451-452
Acetyl choline, effects of alcohol on, 372-373
Alcohol—
  abnormalities of lipid metabolism and, **321-332**
  alimentary system and, **429-445**
  carbohydrate metabolism and, 333-349
  dehydrogenase (ADH)—
    action in vitro, 248-249
    action in vivo, 253-258
    alcohol determination with, 298
    -NADH complex, oxidation of, 261
  determination of in body fluids, 297-300
    breath analysis, 299-300
    chronic excessive consumption, 302-304
    clinical indications for, 301-302
    dichromate reduction, 298
    gas liquid chromatography, 299
    measurement with ADH, 298
    plasma osmolality measurement, 300
    sample handling, 299
  drug metabolism and, 275-292
    acute effects in vitro, 277-279
    acute effects in vivo, 276-277
    chronic effects in the absence of liver disease, 280-286
    chronic effects in the presence of liver disease, 286-292
    chronic effects in vitro, 281-283
    chronic effects in vivo, 280-281
  endocrine effects of, **351-367**
  excessive consumption of, 302-304
  haemopoietic system and, **447-461**
  metabolic effects of, 312-315, 379-380
    acid-base disturbance, 312
    fluid and electrolyte disturbance, 312
    hyperuricaemia, 313
    hypoglycaemia, 313
    lipid abnormalities, 314
    mineral metabolism abnormalities, 314
    porphyria, 314-315
    pseudo-Cushing's disease, 313-314
  metabolic interactions of with other drugs, **273-296**
    postulated bases for, 274-275
    types of, 274
  metabolism of, **247-271**
    direct oxidation of the ADH-NADH complex, 261
    factors affecting, 260
    in chronic consumption, 261-263
    in vitro, 247-252
    in vivo, 252-260
    rate of, 260-265
    regeneration of NAD^+ in, 261
  nervous system and, **385-404**
    acute effects on, 386-389
    chronic effects on, 389-391
    dementia, 399-400
    Wernicke-Korsakoff syndrome, 397-399
    withdrawal symptoms, 391-397
  neurotransmitters and, **369-384**
  nutrition and, **405-428**
  pregnancy and, 423-424
  toxic effects of, 380-381
Alcohol-induced behaviour, 375-377
Alcoholism—
  clinical biochemistry of, **297-319**
  complications of, biochemical identification of, 304-312
  pancreatitis and, 308-310
    acute, 308-309
    chronic, 309-310
  recognition of, 297-304
    biochemical identification of, 297-300
    clinical features of, 297
  withdrawal syndromes, 391-397
    convulsions, 393-394
    delirium tremens, 394-397
    hallucinosis, 392-393
    tremulousness, 392
Aldehyde dehydrogenase, 251-252
Alimentary system, alcohol and, **429-445**
Amblyopia, 401, 423
Amino acid transmitters, effects of alcohol on, 373-374
α-amino-n-butyric acid:leucine ratio, effects of excessive alcohol consumption on, 303
Amnesia, alcoholic, 388-389
Amylase, levels of in pancreatitis, 308, 309
Anaemia—
  causes of, 453-456
    bone marrow changes, 453
    haemodilution, 453
    iron deficiency, 453
    sideroblastic, 453-456
    vacuolization of cell precursors, 453
  megaloblastic, macrocytosis and, 447-450

BERI-BERI heart disease, 311

CALCIUM, effects of alcohol on, 416-417
Carbohydrate metabolism, alcohol and, **333-349**
Cardiac disease—
  alcohol and, 311-312
  ischaemia, alcohol and, 330-331
Cardiomyopathy, alcoholic, 311
Catalase—
  action in vitro, 249
  action in vivo, 252-253
Catecholamines, effects of alcohol on, 361-362
Cell membranes, effects of alcohol on, 377-379
Cerebellar cortical degeneration, 423
  alcoholism and, 400
Cirrhosis, 412, 437
  alcoholic, biochemical identification of, 306-307
  basis for feminization in, 355
  basis for hypogonadism in, 355
  pathogenesis of, 439-441
Convulsions, alcoholic, 393-394
Cyclic nucleotide neuromodulation, effects of alcohol on, 375

DELIRIUM TREMENS, 394-397
Dementia, alcoholism and, 399-400
Dependence, alcohol, 389-391
Depression, neurotransmitters and, 417-419
Diabetic subjects, alcohol effects in, 346
Dichromate reduction, in alcohol determination, 298

ENDOCRINE EFFECTS of alcohol, **351-367**
Erythrocyte δ-aminolaevulinic acid dehydrase, effects of excessive alcohol consumption on, 303-304

FATTY LIVER, alcoholism and, 410
Folic acid deficiency, alcoholic, 419-420
Fructose, alcohol and, 341-343

GALACTOSE, alcohol and, 343-344
γ-glutamyltransferase (GGTP) serum levels, in excessive alcohol consumption, 302-303
Glycogen storage disease, alcohol and, 340-341
Growth hormone, effects of alcohol on, 360-361

HAEMOPOIETIC SYSTEM, alcohol and, **447-461**
Hallucinosis, alcoholic, 392-393
Head injuries, indications for alcohol measurement in, 301
Hepatitis—
  acute alcoholic, biochemical identification of, 305-306
  alcoholic, 410-412, 437, 440-441
    pathogenesis of, 437-439
Hepatoma, biochemical identification of, 307-308
Hyperlipidaemia, alcoholic, management of, 330
Hypertension, alcohol and, 312
Hyperuricaemia, alcohol ingestion and, 313
Hypoglycaemia, 335-340
  alcohol ingestion and, 313
  drug-induced, alcohol potentiation of, 336-337
  'essential' reactive, in alcoholics, 337-338
  fasting, alcohol-induced, 335-336
  reactive, alcohol-induced, 338-340
Hypothalamic-pituitary-adrenocortical axis, effects of alcohol on, 351-355
  animal studies, 351-352
  studies in man, 352-355
Hypothalamic-pituitary-gonadal function, effects of alcohol on, 355-358
  animal studies, 356
  studies in man, 356-358
Hypothalamic-pituitary-thyroid function, effects of alcohol on, 359-360
  animal studies, 359
  studies in man, 359-360

INSULIN SECRETION, alcohol and, 344-345
Intestine, small, effects of alcohol on, 431-433
  absorption effects, 432-433
  metabolic effects, 432
  motility, 432
  structural changes, 432
Intoxication—
  acute, 386-387
  pathological, 387-388

KETOACIDOSIS, alcohol ingestion and, 312-313

LACTIC ACIDOSIS, alcohol ingestion and, 313
Lipaemia—
  alcoholic, clinical manifestations of, 323-326
  alimentary, alcoholic enhancement of, 326-327
Lipase, serum levels in pancreatitis, 309

Lipid levels, serum, mode of effects of alcohol on, 326-329
alterations in VLDL metabolism, 327
enhanced hepatic triglyceride synthesis, 328-329
enhancement of alimentary lipaemia, 326-327
Lipid metabolism, abnormalities of, alcohol and, **321-332**
Lipoproteins—
composition of, 321-322
metabolism of, 322-323
Liver disease—
alcoholic, haemolysis in, 452
alcohol measurements in, 301
identification of, 304-308
Liver, effects of alcohol on, 437-441
cirrhosis, 437, 439-441
fat accumulation, 437-438
fatty liver, 437
hepatitis, 437, 440-441
immunological abnormalities, 439
Mallory's hyaline accumulation, 439
protein accumulation, 439

MACROCYTOSIS—
megaloblastic anaemia and, 447-450
without megaloblastic bone marrow changes, 450
Magnesium, effects of alcohol on, 413-416
Mallory-Weiss syndrome, 431
Marchiafava Bignami disease, 401, 423
Metals, essential biological, 412-417
calcium, 416-417
magnesium, 413-416
potassium, 416-417
zinc, 416-417
Microsomal ethanol-oxidizing system (MEOS)—
action in vitro, 249-251
action in vivo, 258-260
Monoamines, alcohol-induced alterations in metabolism of, 370-372
Mouth, carcinoma of, associated with alcohol consumption, 429-430
Myelinolysis, central pontine, 400-401
Myopathy, alcoholic, 310-311

NERVOUS SYSTEM—
alcohol and, **385-404**
acute effects, 386-389
chronic effects, 389-391
dementia, 399-400
Wernicke-Korsakoff syndrome, 397-399
withdrawal symptoms, 391-397
diseases of, 421-423
vitamins and, 417-420
Neurotransmitters—
alcohol and, **369-384**
depression and, 417-419
functional importance of in alcohol-induced behaviour, 375-377
acute effects of, 375-376
chronic effects of, 376-377
metabolism of, alterations produced by alcohol, 370-375, 377-381
Nicotinic acid deficiency, alcoholic, 420
Nutrition, alcohol and, **405-428**
Nutritional deficiency—
liver disease and, 409-412
mechanisms of, 407-409

OESOPHAGUS, carcinoma of, associated with alcohol consumption, 429-430

PANCREAS, effects of alcohol on, 433-436
epidemiology, 434
pathogenesis of alcohol pancreatitis, 435-436
pathology, 434-435
Pancreatitis—
alcoholic, pathogenesis of, 435-436
alcoholism and, 308-310
acute, 308-309
chronic, 309-310
lipaemia and, 325-326
Peptide transmitters, effects of alcohol on, 374-375
Poisoning, self-, alcohol consumption and, 301
Porphyria, 314-315, 457-458
cutanea tarda symptomatica, 314-315
Potassium, effects of alcohol on, 416-417
Pregnancy, alcohol and, 423-424
Prolactin, effects of alcohol on, 358-359
Prostaglandin neuromodulation, effects of alcohol on, 375
Pseudo-Cushing's disease, alcohol ingestion and, 313-314

RED CELL abnormalities, 450-452
acanthocytosis, 451-452
stomatocytosis, 452
target cells, 450-451
Riboflavin deficiency, alcoholic, 419

SODIUM METABOLISM, effects of alcohol on, 362-363
Steatosis, 440-441
biochemical identification of, 304-305

Stomach, effects of alcohol on, 430-431
gastric emptying, 430
gastric mucosal damage, 430-431
Mallory-Weiss syndrome, 431
Stomatocytosis, 452

TETRAHYDROISOQUINOLINE hypothesis, 372
Thrombocytopenia, 457
Tolerance, alcohol, 389-391
Triglyceride synthesis, mechanisms of alcohol enhanced, 328-329

VITAMINS, alcoholic deficiency of—
B_6, 417-419
B_{12}, 419-420
in alcoholism, 310

WATER METABOLISM, effects of alcohol on, 362-363
Wernicke-Korsakoff syndrome, 397-399, 421-423
White cell abnormalities, 456-457
Withdrawal syndromes, alcoholic, 391-397
convulsions, 393-394
delirium tremens, 394-397
hallucinosis, 392-393
tremulousness, 392

ZINC, effects of alcohol on, 416-417



Index

Note: Page numbers of chapter titles are in **boldface** type.

ADOLESCENCE, hormone levels in, 519-527
Amniotic fluid—
  gonadotrophins in, 495
  sex steroids in, 502-504
    in man, 502-503
    in sub-human primates, 504
Androgens, serum levels of in the fetus, 504-505
Androstenedione, antral fluid levels of, 586, 591, 592

CATECHOLAMINES, in control of GnRH secretion, 534-535
Central nervous system, in regulation of fetal gonadotrophin secretion, 493-494
Childhood—
  follicular growth in, 475-476
    role of hormones in, 477-478
  hormone levels in, 517-519
Chorionic gonadotrophins, *see* Gonadotrophins, placental
Corpus luteum—
  hormonal correlates of formation of, 570
    prolactin and, 571
  LH binding inhibitor and, 614
Cyclic AMP, antral fluid levels of, 589

DOWN'S syndrome, ovarian development in, 481-482

FETUS—
  GnRH responsiveness in, 492
  growth of ovarian follicles in, 472-475
    role of hormones in, 477
  hypothalamic-pituitary gonadotrophin development in, 487-506
  ovarian function in, 505-506
  pituitary gonadotrophins in, **487-511**
  pituitary GnRH receptors in, 492-493
  placental gonadotrophins in, **487-511**
  plasma gonadotrophins in, 489-491
  sex steroids in, **487-511**
    receptors for, 493
  sexual differentiation of brain of, 496
Follicle, *see also* Ovary—
  antral fluid hormone concentrations, **577-600**
  atresia of during menstrual cycle, 561-562, 563-564
  atretic, hormonal determination of, 571-572
  biochemical changes during maturation, 601-603
  classification of, 469-472
    antral, 472
    pre-antral, 470-472
    small, 470
  cystic, hormones in fluid of, 590
  fluid, inhibition of FSH action by, 607-608, 614-616
  granulosa cell numbers in, 578
  growth—
    after puberty, hormonal correlates of, **561-575**
    during menstrual cycle, 561-562, 563-564
    intrafollicular control of, 594-596
    preovulatory, decreased gonadotrophin levels and, 564-567
    prepubertal, **469-485**
      in disease, 478-480
      role of hormones in, 477-478
  ovulatory, hormonal determination of, 571-572
  preovulatory, hormone levels and, 567-570
  ruptured, hormones in fluid of, 589-590
  rupture of, events involved in, 612-614
Follicle-stimulating hormone, *see* Gonadotrophins
Folliculostatin, *see* Inhibin

GONADOTROPHINS—
  effects of progesterone on release of, 540-543
    negative feedback, 541
    positive feedback, 541-543
  effects of ratios of, 568-569
  follicular fluid inhibition of FSH actions, 607-608
  in amniotic fluid, 495
  in antral fluid, 579-584, 591
    FSH, 580, 591, 592
    LH, 581, 592-593
    prolactin, 581-582, 592
    subunits, 583-584

Gonadotrophins (*Continued*)
ovulation induction with, 568
pituitary, in the fetus, **487-511**
placental, in the fetus, **487-511**
plasma, in the fetus, 489-491
prepubertal levels of, **513-530**
subunits of, 491-492
Gonadotrophin-releasing hormone (GnRH), 543-547
effects of administration of in man, 543-544
effect of oestrogen on response to, 544-547
effect of progesterone on response to, 549-550
fetal pituitary receptors for, 492-493
fetal responsiveness to, 492
mid-cycle surge, 548-549
modulatory role of catecholamines on secretion of, 534-535
priming effect of, 547-550
regulation of pituitary secretion by, 534
synthesis of, 487-488

HYPOTHALAMIC-PITUITARY axis, anatomy of, 532-533
Hypothalamus—
development of, 487-488
regulation of pituitary secretion by, 534-535
sex steroid receptors in, 493

INFANCY, hormone levels in, 514-517
Inhibin, 614-616
antral fluid levels of, 589

LEUKAEMIA, ovarian development in, 478-479
Luteinization, hormonal control of, **601-624**
Luteinizing hormone, *see* Gonadotrophins

MENOPAUSE, **625-643**
clinical implications of, 636-638
hormone metabolism after, 632-635
menopausal syndrome, 636
perimenopausal state, 625-632
Menstrual cycle—
follicle growth and atresia during, 561-562, 563-564
follicular phase, 551-552
hormonal events during, 535-537, 562-564
luteal phase, 552
short, 570-571
mechanism of preovulatory LH surge, 552
neuroendocrinology of in man, **531-559**
history of, 531-532

OESTROGENS—
antral fluid levels of, 587-589, 591, 592
effects of on follicular growth, 569-570
effects of on response to GnRH, 544-547
negative feedback of, 537-538
positive feedback of, 538-539
dynamics of, 539-540
secretion during human gestation, 496-498
biological significance of, 498
secretion during sub-human primate gestation, 499-500
Olfactogenital dysplasia, 564-565
Oocyte meiosis, hormonal control of, **601-624**
Oral contraceptives, effects of on follicular growth, 565-567
Ovary, *see also* Follicle—
development of, chromosomal abnormalities and, 480-482
development of in disease, 478-480
abdominal tumours, 479-480
leukaemia, 478-479
feedback of steroids from, 537-540
dynamics of positive feedback, 539-540
negative feedback, 537-538
positive feedback, 538-539
fetal, 505-506
formation of, 469
hormones of in antral fluid, 584-589
in pregnancy, 568-569
prepubertal, follicular growth in, **469-485**
sclerocystic, 569
Ovulation—
gonadotrophin induced, 568
hormonal control of, **601-624**

PLACENTA—
gonadotrophins from, **487-511**
sex steroid secretion and, 496-504
in amniotic fluid, 502-504
oestrogens, 496-500
progesterone, 500-502
Pregnancy, ovary in, 568-569
Pregnenolone, levels of in antral fluid, 584-585
Progesterone—
antral fluids of, 586, 592-593
effect of on gonadotrophin release, 540-543
negative feedback, 541
positive feedback, 541-543
effect of on gonadotrophin-releasing hormone response, 549-550
physiological significance of, 502
secretion of during human gestation, 500-501
secretion of during sub-human primate gestation, 501-502
Prolactin, *see also* Gonadotrophins—
corpus luteum function and, 571
in antral fluid, 581-582
Prostaglandins, antral fluid levels of, 589

Puberty—
follicle growth after, hormonal correlates of, **561-575**
follicle growth before, **469-485**

RECEPTORS—
GnRH, in fetal pituitary, 492-493
sex steroid, in fetus, 493
Relaxin, antral fluid levels of, 589

SEXUAL DIFFERENTIATION—
of fetal brain, 496
role of hormones in, 504-506
fetal ovarian function, 505-506
fetal serum androgens, 504-505
Steroid hormones, *see also* Androgens, Oestrogens, or Progesterone—
prepubertal levels of, **513-530**
role of in follicular growth, 477-478

TESTOSTERONE, antral fluid levels of, 586-587
Trisomy 18, ovarian development in, 481
Trisomy 21, ovarian development in, 481-482
Tumours, abdominal, ovarian development with, 479-480
Turner's syndrome, ovarian development in, 480-481